Study of Topical Minocycline For Acne Demonstrates No Phototoxicity or Absorption Interview with:
Kin F. Chan, PhD

Executive Vice President of Research and Technology
BioPharmX Corporation What is the background for this study? What are the main findings?

Response: There were two studies in this series.  The purpose is to get a better understanding of the blood plasma and skin levels of minocycline in a relevant animal model (minipig) for both the oral form of minocycline (Solodyn) and topical BPX-01, and to elucidate the same for oral minocycline only in a clinical study.

The results provided valuable guidance and assurance to our upcoming Clinical Phase 2b dose-ranging study design. What should readers take away from your report?

Response: There are a few key take-aways for this study:

(1) Oral Solodyn resulted in significant systemic level of minocycline which is known to cause severe adverse effects, while topical BPX-01 did not produce detectable plasma level of minocycline.

(2) Topical 1% BPX-01 delivered significant amount of minocycline to the skin in a targeted manner, while no detectable level of minocycline was found in the skin in the oral minocycline group.

(3) 1% BPX-01 was shown to be well tolerated after 28 days of daily topical application.  No phototoxicity or photosensitivity was noted throughout the study duration.

(4) The overall results provide reassurance and confidence to our clinical Phase 2b dose-ranging study design. What recommendations do you have for future research as a result of this study?

Response: In addition to this study, our clinical Phase 2a P. acnes reduction study results provided further validation of the strength and potential of BPX-01 success in our upcoming Phase 2b and Phase 3 trials. Thank you for your contribution to the community.Citation:

Dermatology Education Foundation 2016 abstract discussing:

Comparative studies of oral and topical minocycline formulations

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on

[wysija_form id=”5″]




    Re: Interview Invitation
Nina Brauer <[email protected]> (Add as Preferred Sender)
Date: Wed, Aug 10, 2016 1:46 pm
To: [email protected]” <[email protected]>

Nina Brauer

Sr. Manager Marketing & Communications

1098 Hamilton Court  |  Menlo Park, CA  |  94025

Office (650) 889-5030  |  Mobile (843) 557-4290




——– Original Message ——–
Subject: Re: Interview Invitation
From: Nina Brauer <[email protected]>


Last Updated on August 15, 2016 by Marie Benz MD FAAD